Nuzenio

Glucagon

Glucagon news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 7 publisher sources 100/100 entity strength

Latest news

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH - The American Journal of Managed CareThe American Journal of Managed Care · Sat, 08 Aug 2026 04:39:05 GMT Neurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity - biopharminternational.combiopharminternational.com · Fri, 07 Aug 2026 17:19:41 GMT Neurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study - AllSciAllSci · Fri, 07 Aug 2026 16:26:00 GMT New review highlights FOXA2's role in glucose regulation pathways - News-MedicalNews-Medical · Thu, 06 Aug 2026 04:12:00 GMT Medicare expands GLP-1 weight loss drug coverage, Grand Strand clinics see patient surge - WMBFWMBF · Wed, 05 Aug 2026 19:55:00 GMT Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Hematological Malignancies: A Narrative Review of Current and Emerging Evidence - CureusCureus · Wed, 05 Aug 2026 14:46:24 GMT Renoprotective effects of tubular glucagon receptor activation mediated by V-ATPase - Science | AAASScience | AAAS · Wed, 05 Aug 2026 07:00:00 GMT

Timeline

Sat, 08 Aug 2026 04:39:05 GMTGLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH - The American Journal of Managed Care

Fri, 07 Aug 2026 17:19:41 GMTNeurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity - biopharminternational.com

Fri, 07 Aug 2026 16:26:00 GMTNeurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study - AllSci

Thu, 06 Aug 2026 04:12:00 GMTNew review highlights FOXA2's role in glucose regulation pathways - News-Medical

Wed, 05 Aug 2026 19:55:00 GMTMedicare expands GLP-1 weight loss drug coverage, Grand Strand clinics see patient surge - WMBF

Wed, 05 Aug 2026 14:46:24 GMTGlucagon-Like Peptide-1 (GLP-1)-Based Therapies and Hematological Malignancies: A Narrative Review of Current and Emerging Evidence - Cureus

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

GLP9 live mentions Obesity4 live mentions GIP4 live mentions Plus Glucagon2 live mentions The Mechanistic Case2 live mentions Dual Receptor Agonism2 live mentions Neurocrine Biosciences Begins2 live mentions Phase2 live mentions Study2 live mentions Glucagon Triple Agonist2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Glucagon.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.